A Prospective Clinical and Transcriptomic Feasibility Study of Oral‐only Hormonal Therapy with Radiation for Unfavorable Prostate Cancer in Men 70 Years of Age and Older or with Comorbidity

Androgen deprivation therapy (ADT) improves outcomes in unfavorable‐risk prostate cancer (PCa) treated with radiation therapy (RT). It was hypothesized that replacing luteinizing hormone‐releasing hormone (LHRH) agonists with a 5‐α‐reductase inhibitor (5‐ARI) would improve hormonal health‐related quality of life (HRQOL) without differentially suppressing androgen‐responsive (AR) gene expression.